Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:POLBF)

0.0425 UNCHANGED
Last Price Updated: 11:43 AM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about POLBF

< Previous 1 2 3 Next >
Poolbeg Pharma PLC Announces Voluntary Delisting from OTCQB Market
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Change of Registered Address
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Annual Report & AGM Notice
Via ACCESSWIRE
Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chief legal officer John McEvoy joins Proactive's Stephen Gunnion with news that POLB 001's Immuno-modulator II has received the fully granted patent from the... 
Via TheNewswire.com
Topics Intellectual Property
Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USA
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2023
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate
Via ACCESSWIRE
Poolbeg Pharma PLC Announces TR-1: Notification of Major Holdings
Via ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 US Patent Update
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRS
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Appointment of Joint Broker
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Director Share Purchase
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRS
Via ACCESSWIRE
Poolbeg Pharma PLC Announces RSV AI Drug Candidate Analysis Update
Via ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 Data Presented at ASH
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Directorate Change
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Immunomodulator II Patent Granted in Japan
Via ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 LPS Trial Data to be Presented at IUIS
Via ACCESSWIRE
Former Amryt Pharma Leadership Team join Poolbeg
Via ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 Data to be Presented at American Society of Hematology Annual Meeting
Via ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 Oncology Programme Update Meeting
Via ACCESSWIRE
Poolbeg Pharma unveils new collaboration agreement
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the pharma & biotech company has signed a new collaboration agreement with an... 
Via TheNewswire.com
Poolbeg Partners with a Nasdaq-Listed Biopharma
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Immunomodulator I Patent Opposition Withdrawal
Via ACCESSWIRE
Poolbeg Pharma "moving forward rapidly" with POLB001
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the pharma & biotech's interim results for the six months to 30 June 2023.... 
Via TheNewswire.com
Topics Artificial Intelligence
Poolbeg Pharma PLC Announces Interim Results for the Six Months to 30 June 2023
Via ACCESSWIRE
Poolbeg Pharma PLC Announces AI Led Programme Identifies Influenza Drug Targets
Via ACCESSWIRE
Poolbeg Pharma and CytoReason identify "very exciting influenza targets"
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant... 
Via TheNewswire.com
Topics Artificial Intelligence
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.